Evidence map›Paper›PMID 32629687›Full record

ArticleMedicine2020

Occurrence of the S230R integrase strand inhibitor mutation in a treatment-naïve individual case report.

Smitha Gudipati, Indira Brar, Alicia Golembieski, Zachary Hanna, Norman Markowitz

Open access · goldAbstract readCase Reports
In one paragraph

Article in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 3 countries.

Smitha GudipatiDepartment of Infectious Disease, Henry Ford Hospital, Detroit, MI.ORCID -362
Indira Brar
Alicia Golembieski
Zachary Hanna
Norman Markowitz
Henry Ford Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleTransmitted resistance to integrase strand inhibitors (INSTI) has been uncommon, but is slowly becoming more prevalent among those living with HIV. In an era with 2-drug regimens for antiretroviral therapy, transmitted resistance for INSTI is alarming. PATIENT CONCERNS: A 28-year-old African American female was recently diagnosed with HIV during a 30-week prenatal visit. DIAGNOSIS: HIV 4th generation test was positive as well as confirmation. Genotype was performed using next generation sequencing.

interventionsPatient was initially rapidly started on a dolutegravir based regimen and changed to a protease inhibitor regimen once her genotype reported an S230R mutation. OUTCOMES: Patient became virally suppressed on antiretroviral therapy and delivered an HIV negative baby. LESSONS: INSTI resistance testing should be done for treatment-naïve and INSTI-naïve persons, particularly when considering 2 drug INSTI based regimens.

Indexed as

Drug Resistance, ViralPrenatal DiagnosisAdultFemaleGenotypeHIV-1HIV InfectionsHIV Integrase InhibitorsHumansMutationPregnancyPregnancy Complications, InfectiousProtease InhibitorsHIV Integrase InhibitorsProtease Inhibitors

Identifiers

PMID32629687
PMCPMC7337458
OpenAlexW3039091485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.